Clinical trials: SARS-COV2 Virus
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Enteral Nutrition, COVID-19 Acute Respiratory Distress Syndrome
Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
The goal of this observational study is to determine the relationship between the nutritional profile of critically ill patients diagnosed with COVID-19 and disease severity, prognosis, and survival, to assess the ability to meet…
- Trial name
- NCT06134674
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people
- Sponsor
- Ankara City Hospital Bilkent
SARS-CoV-2 Infection
A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults…
- Trial name
- COVID-19 (NCT05112848)
- Testing
- NVX-CoV2373
- Where
- 7 sites in South Africa
- Volunteers
- 384 people
- Sponsor
- Novavax
Long COVID, Long Coronavirus Disease 2019 (Covid19)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Trial name
- NCT06305793
- Testing
- IVIG (intravenous immunoglobulin), Coordinated Care, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Kanecia Obie Zimmerman
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19 Respiratory Infection
Evaluation of Peripheral Muscle With Ultrassonografic of Critical Patients With Covid-19
Currently, the tools available for assessing peripheral muscle dysfunction in the intensive care setting require patient collaboration.
- Trial name
- NCT05055440
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Pernambuco
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study
To examine the efficacy of an 8-week exercise training program on functional, cognitive, and emotional health outcomes compared to a no treatment control condition in adults with PASC.
- Trial name
- PASC (NCT05218174)
- Testing
- Exercise Prescription
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor Research Institute
Coronavirus Infection, COVID
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
Specific Aims: 1. The investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisition of focused point-of-care ultrasound images in a cohort of patients with or…
- Conditions
- Coronavirus Infection, COVID, Covid-19, SARS-CoV-2
- Trial name
- NCT04339998
- Testing
- Point-of-Care Ultrasonography (POCUS)
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Minnesota
COVID-19, SARS-CoV-2 Infection
PERC Health Canada COVID-19
Although there are several licensed vaccines for SAR-CoV-2 (COVID-19) in Canada, none of them are approved for use in children under the age of 12, leaving five million children under 12 years unvaccinated.
- Trial name
- NCT05040763
- Testing
- Buccal Swabc- Copan flocked swab, Standard of Care COVID-19 swab
- Where
- 13 sites in Canada
- Volunteers
- 7,263 people
- Sponsor
- University of Calgary
Covid19
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19.
- Trial name
- NCT05009732
- Testing
- GT0918, Standard of care
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 139 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
COVID-19
Vitamin D for COVID-19 Trial
The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs.
- Trial name
- VIVID (NCT04536298)
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 2,024 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
SARS-CoV 2
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several…
- Trial name
- CoviDiagMS (NCT04460638)
- Testing
- Saliva collection, Clinical assessment
- Where
- France
- Volunteers
- 779 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Covid19
[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse
The purpose of this study is to test the effectiveness of prophylactic mouth rinses in reducing the amount of viruses, specifically SARS-CoV-2 in the oral cavity.
- Trial name
- NCT04719208
- Testing
- Water (E) Mouth rinse with the solution provided, Chlorhexidine gluconate (A) Mouth rinse with the solution provided, Hydrogen peroxide (B) Mouth rinse with the solution provided
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
SARS-CoV 2 Infection, Covid19
Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
Coronavirus disease 2019 (COVID-19) is potentially a deadly disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that targets the lung mainly, resulting in respiratory tract infections in humans.
- Trial name
- NCT04993560
- Testing
- BBIBP-CorV, BNT162b2
- Where
- Bahrain
- Volunteers
- 305 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Covid-19 (SARS-CoV-2)
Incidence of Infection Reported by COVID-19 in Attendees of a Commercial Music Concert
From the beginning of the pandemic caused by SARS-CoV-2, most events with massive participants have been canceled due to being considered high-risk events for the SARS-CoV-2 transmission.
- Trial name
- NCT04824625
- Where
- Spain
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
COVID, SARS (Severe Acute Respiratory Syndrome)
Low Dose Radiotherapy in COVID-19 Pneumonia
Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.
- Trial name
- NCT04390412
- Testing
- Low Dose Radiotherapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Respiratory Infections
Study of Viral Respiratory Infections
Acute viral respiratory infections are a major public health problem, as they cause mortality especially in pediatric patients, over 65 and those with co-morbidities.
- Trial name
- NCT06764381
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Virus Diseases
Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Coronary Heart Disease
- Trial name
- ACTIVATEII (NCT04414267)
- Testing
- BCG vaccine
- Where
- 15 sites in Greece
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis